Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

被引：47
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
来源：
LIVER CANCER | 2022年 / 11卷 / 05期
关键词：
Atezolizumab plus bevacizumab; Hepatocellular carcinoma; ABC conversion; Curative therapy; Cancer-free status; Drug-free status; POSITRON-EMISSION-TOMOGRAPHY; T-CELL RESPONSES; RADIOFREQUENCY ABLATION; F-18-FDG PET/CT; TUMOR; LENVATINIB; DIFFERENTIATION; IDENTIFICATION; ENHANCEMENT; MULTICENTER;
D O I：
10.1159/000526163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399 / 406
页数：8
相关论文
共 50 条
  • [31] Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishikawa, Hiroki
    Nishimura, Takashi
    Kawata, Kazuhito
    Kosaka, Hisashi
    Naganuma, Atsushi
    Yata, Yutaka
    Ohama, Hideko
    Kuroda, Hidekatsu
    Matono, Tomomitsu
    Aoki, Tomoko
    Kanayama, Yuki
    Tanaka, Kazunari
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Nakamura, Shinichiro
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1361 - 1373
  • [32] Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture
    Miyata, Tatsunori
    Sugi, Kazuhiro
    Horino, Taichi
    Ono, Asuka
    Tagayasu, Yoshiyuki
    Nomoto, Daichi
    Inoue, Mitsuhiro
    Mizumoto, Takao
    Kubota, Tatsuo
    Yanagida, Eriko
    Murayama, Toshihiko
    Miyanari, Nobutomo
    Baba, Hideo
    ANTICANCER RESEARCH, 2023, 43 (02) : 943 - 947
  • [33] Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
    Hatanaka, Takeshi
    Yata, Yutaka
    Naganuma, Atsushi
    Kakizaki, Satoru
    CANCERS, 2023, 15 (06)
  • [34] OPTIMAL MANAGEMENT OF ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA FOCUSING ON THERAPEUTIC MODIFICATIONS
    Tokunaga, Takayuki
    Tateyama, Masakuni
    Kondo, Yasuteru
    Miuma, Satoshi
    Miyase, Shiho
    Tanaka, Kentaro
    Narahara, Satoshi
    Inada, Hiroki
    Kurano, Sotaro
    Yoshimaru, Yoko
    Nagaoka, Katsuya
    Watanabe, Takehisa
    Setoyama, Hiroko
    Tanaka, Yasuhito
    HEPATOLOGY, 2022, 76 : S1351 - S1352
  • [35] Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study
    Ueno, Masaki
    Kosaka, Hisashi
    Iida, Hiroya
    Ida, Yoshiyuki
    Aoi, Kazunori
    Mori, Haruki
    Miyamoto, Atsushi
    Nishida, Yuko
    Hayami, Shinya
    Kawai, Manabu
    Kaibori, Masaki
    ONCOLOGY, 2023, 101 (09) : 565 - 574
  • [36] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    JAMA NETWORK OPEN, 2021, 4 (04)
  • [37] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Mah I Kan Changez
    Maimoona Khan
    Muhammad Uzair
    Muhammad Fawad Tahir
    Maryam Mohsin
    Amna Faiyaz Hussain
    Vania Saqib
    Muhammad Khizer Molani
    Aisha Habib Ahmed
    Saad Khalid
    Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481
  • [38] ASSESSING ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS WITH ESOPHAGEAL-GASTRIC VARICES
    Tada, Fujimasa
    Hiraoka, Atsushi
    Hatanaka, Takeshi
    Tada, Toshifumi
    Kakizaki, Satoru
    Kumada, Takashi
    GASTROENTEROLOGY, 2024, 166 (05) : S1730 - S1730
  • [39] The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients
    Aranda-Gutierrez, Alejandro
    Conde-Flores, Emilio
    Meraz-Brenez, Andres
    Escorza, Salvador
    Meneses-Medina, Monica I. Isabel
    Huitzil-Melendez, Fidel David
    de la Mora-Molina, Hector
    Rosas Camargo, Vanessa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Tani, Joji
    Hirooka, Masashi
    Takaguchi, Koichi
    Atsukawa, Masanori
    Fukunishi, Shinya
    Itobayashi, Ei
    Tsuji, Kunihiko
    Tajiri, Kazuto
    Ochi, Hironori
    Ishikawa, Toru
    Yasuda, Satoshi
    Ogawa, Chikara
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Nishimura, Takashi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Shimada, Noritomo
    Tada, Fujimasa
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Ohama, Hideko
    Morishita, Asahiro
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Kosaka, Hisashi
    Imai, Michitaka
    Naganuma, Atsushi
    Nakamura, Shinichiro
    Koizumi, Yohei
    Matono, Tomomitsu
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (04) : 270 - 281
12345